Table 1 Characteristics at baseline of the rheumatoid arthritis cohort
| Â | ACPA-positive | ACPA-negative | ACPA-positive | ACPA-negative |
|---|---|---|---|---|
RF-negative | RF-negative | |||
Numbers | 125 | 58 | 14 | 45 |
Age, years | 48 (40–56) | 58 (52–64) | 43 (29–50) | 59 (55–65) |
Female sex | 97 (78 %) | 35 (60 %) | 11 (79%) | 27 (60 %) |
Ever smoking | 71 (66 %) | 36 (67 %) | 7 (64 %) | 28 (67 %) |
HLA-DRB1 SE | 109 (89 %) | 34 (60 %) | 13 (100 %) | 25 (57 %) |
PTPN22 risk allele | 40 (33 %) | 10 (18 %) | 5 (38 %) | 6 (14 %) |
DAS28-ESR | 5.6 (5.0–6.2) | 5.8 (5.1–6.3) | 6.0 (5.2–6.2) | 5.9 (5.1–6.3) |
ESR | 28 (16–40) | 23 (12–39) | 28 (25–35) | 21 (12–35) |
HAQ | 1.1 (0.8–1.6) | 1.3 (0.9–1.5) | 1.0 (0.8–1.5) | 1.3 (0.9–1.5) |
Prednisolone | 16 (13 %) | 10 (18 %) | 1 (7 %) | 7 (16 %) |
Calcium and/or vitamin D supplement | 7 (6 %) | 3 (5 %) | 1 (7 %) | 1 (2 %) |
Hormone replacement therapy | 9 (7 %) | 7 (12 %) | 0 (0 %) | 5 (11 %) |
RF-positive | 111 (89 %) | 13 (22 %) | Â | Â |
Anti-cit-enolase (amino acids 5–21)+ | 73 (58 %) | 0 (0 %) | 6 (43 %) | 0 (0 %) |
Anti-cit-vimentin (amino acids 60–75)+ | 65 (52 %) | 0 (0 %) | 7 (50 %) | 0 (0 %) |
Anti-cit-fibrinogen (amino acids 563–583)+ | 39 (31 %) | 1 (2 %) | 2 (14 %) | 1 (2 %) |